LEXEO THERAPEUTICS INC (LXEO)
Health Care · Genetic medicine / gene therapy for rare cardiovascular diseases · NASDAQ
Lexeo is a clinical-stage genetic medicine company developing gene therapies targeting the genetic root causes of rare cardiovascular diseases like Friedreich ataxia cardiomyopathy.
What LEXEO THERAPEUTICS INC does
Lexeo Therapeutics is a clinical-stage genetic medicine company developing therapeutic candidates to treat cardiovascular diseases by targeting underlying genetic causes. The company's lead program, LX2006, is being evaluated in Phase 1/2 trials for Friedreich ataxia cardiomyopathy, with additional programs targeting cardiomyopathy associated with PKP2 mutations and arrhythmogenic cardiomyopathy. The company focuses on applying pioneering genetic medicine science to reshape treatment of cardiovascular diseases with high unmet medical need.
Themes: Genetic medicine / gene therapy, Cardiovascular disease treatment, Rare genetic cardiomyopathies, Clinical-stage therapeutics, Friedreich ataxia
Fundamentals
- Price$4.88 as of 2026-08-21 close
- Market cap$400M as of 2026-08-21
- 1-year return+2.1% 2025-08-21 close $4.78 → 2026-08-21 close $4.88
- P/En/a negative earnings
- Net margin-11991.8% as of 2026-08-24
- ROE-47.5% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta1.49 as of 2026-08-24
- Last reported earnings2026-08-12 SEC EDGAR Form 8-K (Item 2.02)
How LXEO compares in its sector
- net profit marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How LEXEO THERAPEUTICS INC looks technically
LEXEO THERAPEUTICS INC (LXEO) is trading 27.5% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 97 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 17, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 52, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 3 trading days ago. It is 55.6% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 27.5% below its 200-day average, the long-term trend line — a long-term downtrend | -27.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $4.70 | $4.70 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $6.73 | $6.73 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 18 calendar days ago — the swings before that are what the structure reading is measured on | 18 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 3.99. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 97 trading days ago — a "death cross", a bearish long-term signal | 97 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 17, below the 25 that marks a real trend) | 16.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 52, neither overbought (above 70) nor oversold (below 30) | 52.2 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($4.22 to $5.41) — its "stochastic" reading is 56 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 55.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 12 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $10.99 | $10.99 |
|---|---|---|
| From the 52-week high | it is 55.6% below its 52-week high (its highest price of the past year) | -55.6% |
| Above the 52-week low | it is 22.3% above its 52-week low (its lowest price of the past year) | +22.3% |
| Below the 52-week high | it is 55.6% below its highest point of the past year | 55.6% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $22.33 (set on 2024-01-18) | $22.33 |
| Given back of the 52-week move | over the past year its closes ranged ($4.13 to $10.63), and it has recovered only a small part of its fall from last year’s high — 12% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $8.15 to $8.36. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 11.5% |
| From the all-time high | it is 78.1% below its all-time high | -78.2% |
| Nearest price level | it is sitting right on a support level at $4.87 — a price it turned at twice since 2025-07-07, most recently on 2025-09-12. Since 2024-08-21 it has 6 such levels below the current price and 11 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.2% |
| All-time low | its lowest closing price on record is $1.45 (set on 2025-04-07) | $1.45 |
| Above the all-time low | it is 236.6% above its all-time low | +236.6% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 59th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.3211 between its high and its low — about 6.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.3211 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $4.03 and $5.31 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $4.03 – $4.67 – $5.31 |
| Typical daily range (% of price) | its price moves about 6.6% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.6% |
| Stretch from the 200-day average | it is trading 5.8 daily ranges below its 200-day average price (27.5% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 5.8 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.53× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 2.8% since the prior reading | -2.8% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has softened toward "sell" since the prior reading | 0.02 toward sell |
Candlestick patterns
3
| Since a doji | 3 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 3 sessions ago |
|---|---|---|
| Since a bullish engulfing | 4 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 4 sessions ago |
| Since a bearish engulfing | 5 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 5 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 1.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.2% |
|---|---|---|
| Gap filled | a 2.8% gap up opened on 2026-08-19 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it took 1 session to close | 1 session ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -9.12% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 2.4 percentage points (the stock gained 4.7% while the market gained 2.3%) | +2.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 9.8 percentage points (the stock lost 6.7% while the market gained 3.1%) | -9.8% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 33.5 percentage points (the stock lost 22.4% while the market gained 11.1%) | -33.5% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 18.4 percentage points (the stock gained 2.1% while the market gained 20.5%) | -18.4% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a fresh 20-day high, MACD momentum is positive — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 8.9% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 19% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $6.03 — a volume-weighted average of daily closes over 154 sessions, not a true tick-by-tick VWAP. | -19.0% |
|---|
Price levels it has turned at before
LXEO last closed at $4.88 on 2026-08-21. Since 2024-08-21 it has turned at 6 prices below its last close and 11 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $4.87 | Support | 0.2% below the last close | turned there twice · 2025-07-07 to 2025-09-12 |
| $5.01 | Resistance | 2.6% above the last close | turned there four times · 2025-07-30 to 2026-07-22 |
| $4.50 | Support | 7.8% below the last close | turned there twice · 2025-06-25 to 2025-08-26 |
| $4.42 | Support | 9.5% below the last close | turned there twice · 2026-05-19 to 2026-07-16 |
| $5.36 | Resistance | 9.8% above the last close | turned there twice · 2026-06-18 to 2026-07-09 |
| $5.54 | Resistance | 13.6% above the last close | turned there twice · 2025-05-02 to 2026-05-01 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $3.99.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Broke out to a new 20-day high · trendless / choppy (low ADX) · Analyst price target recently CUT · lagging the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.22 mean, 1=Strong Buy…5=Strong Sell) — 10 analysts
- Mean price target$20.30 range $9.00 – $30.00; median $20.00
Analyst estimates, as of 2026-08-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for LXEO
- Consensus EPS estimate-$0.2786 next reporting period, as of 2026-08-22
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Early clinical stage with only Phase 1/2 data; pivotal study results and regulatory approval remain uncertain","Reliance on third-party manufacturing partners to comply with significant manufacturing regulations and achieve scalability for commercial viability","Small patient populations for rare genetic cardiovascular diseases may limit market opportunity and patient enrollment in trials"]
What changed in the latest 10-Q
AI-assisted comparison of LXEO's 10-Q filed 2026-05-11 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Added 'Overview' section header (newer filing, 2026-05-11)
- Added statement: 'LX2006 for the treatment of FA cardiomyopathy' as subsection header (newer filing, 2026-05-11)
- Added detailed interim clinical data from October 2025 update including LVMI improvements in 6 participants, secondary cardiac biomarkers (troponin I, LWT), and mFARS improvements (newer filing, 2026-05-11)
- Added reference to April 2025 data on frataxin protein expression increases (newer filing, 2026-05-11)
- Added March 2026 ACC Annual Meeting presentation details with statistically significant mFARS score improvements compared to propensity-matched control cohort (newer filing, 2026-05-11)
- Added detailed safety information: no Grade 3 treatment-related SAEs, no clinically significant complement activation, minimal transient LFT elevations, no frataxin over-expression in cardiac tissue, one possibly treatment-related Grade 2 asymptomatic myocarditis event one year after dosing (newer filing, 2026-05-11)
- Added 'Regulatory Alignment' section header (newer filing, 2026-05-11)
- Added February 2025 RMAT meeting details on frataxin expression co-primary endpoint alignment (newer filing, 2026-05-11)
- Added July 2025 Breakthrough Therapy designation announcement (newer filing, 2026-05-11)
- Added CDRP Program selection details (newer filing, 2026-05-11)
- Added February 2026 SAP submission details and FDA feedback status (newer filing, 2026-05-11)
- Added 'LX2020 for the treatment of arrhythmogenic cardiomyopathy' as subsection header (newer filing, 2026-05-11)
- Added 'Interim Clinical Data Updates' section header for LX2020 (newer filing, 2026-05-11)
- Added January 2026 interim clinical data update with 10 participants dosed and 8 with 6-month follow-up (newer filing, 2026-05-11)
- Added arrhythmia burden improvements: NSVT 22% mean improvement in high-dose cohorts, PVCs 14% mean improvement (newer filing, 2026-05-11)
- Added PGIC scale data: 4 of 5 high-dose participants report improvement (newer filing, 2026-05-11)
- Removed:
- Removed 'Recent developments' section header (older filing, 2025-11-05)
- Removed detailed discussion of manufacturing process comparability between HEK293 and Sf9-baculovirus platforms (older filing, 2025-11-05)
- Removed November 2025 FDA approval of analytical comparability report (older filing, 2025-11-05)
- Removed statement about meeting additional nonclinical requirement for manufacturing (older filing, 2025-11-05)
- Removed specific dose cohort breakdown for LX2020: 'three in the low dose cohort 1 (2×10^13 vg/kg), three in the high dose cohort 2 (6×10^13 vg/kg), and four in the dose-expansion high dose cohort 3' (older filing, 2025-11-05)
- Removed October 2025 report of Grade 3 SVT serious adverse event details and participant medical history (older filing, 2025-11-05)
- Removed low-dose cohort detailed data table with arrhythmia burden, electrical activity, and cardiac function metrics (older filing, 2025-11-05)
- Removed statement: 'We anticipate sharing additional safety and clinical efficacy data in January 2026 at the J.P. Morgan Healthcare Conference' (older filing, 2025-11-05)
- Removed information about cardiac biopsies from high-dose cohorts (older filing, 2025-11-05)
- Removed detailed discussion of AAVrh10 vector rationale (older filing, 2025-11-05)
- Removed 'Public offering' section with October 20, 2025 details (17,968,750 shares at $8.00, $134.6M proceeds) (older filing, 2025-11-05)
- Removed 'Private placement' section with October 20, 2025 pre-funded warrant details (1,250,015 warrants, $9.3M proceeds) (older filing, 2025-11-05)
- Removed 'Current and future capital requirements' section header and opening text (older filing, 2025-11-05)
- Reworded:
- Changed structure: older filing used 'Recent developments' as umbrella section with narrative flow; newer filing reorganized into discrete subsections with headers ('Overview', 'LX2006 for the treatment of FA cardiomyopathy', 'Interim Clinical Data Updates', 'Regulatory Alignment', 'LX2020 for the treatment of arrhythmogenic cardiomyopathy')
- Older filing integrated regulatory and clinical data in chronological narrative; newer filing separated regulatory alignment into distinct section
- Older filing presented low-dose LX2020 data in tabular format with specific parameters; newer filing presents combined high-dose and low-dose data in narrative bullet points
- Older filing discussed manufacturing comparability as key regulatory development; newer filing references manufacturing only briefly in context of already-completed FDA approval
- Notes:
- The newer filing text is truncated mid-sentence ('Participants stable across other clinical measures including QRS duration, T-wave inversion, right ve'), affecting completeness of comparison for LX2020 section
- Cannot assess whether removed sections (public offering, private placement, capital requirements) were moved to different sections of the newer filing or entirely removed
Risk Factors
- Added:
- Newer filing (2026-05-11) adds cash flow table for three months ended March 31, 2026 and 2025, replacing the nine months ended September 30 comparison in older filing
- Newer filing adds reference to warrant exercise proceeds of $2.4 million in financing activities section
- Newer filing updates critical accounting reference to audited financial statements for year ended December 31, 2025 with Form 10-K filed March 30, 2026
- Removed:
- Older filing (2025-11-05) cash flow table for nine months ended September 30, 2025 and 2024 removed in newer filing
- Older filing reference to May 2025 Private Placement offering of $73.1 million removed in newer filing
- Older filing reference to net loss of $79.0 million and $72.4 million for nine-month periods removed
- Older filing reference to unrealized gain of $3.4 million on convertible preferred stock investment removed
- Older filing reference to stock option exercise proceeds removed in newer filing
- Older filing critical accounting reference to audited financial statements for year ended December 31, 2024 with Form 10-K filed March 24, 2025 removed
- Reworded:
- Cash flow period changed from nine months ended September 30 to three months ended March 31
- Operating activities narrative updated from $79.0 million net loss to $20.2 million net loss
- Investing activities narrative changed from $11.4 million provided to $27.5 million provided
- Financing activities narrative changed to reference warrant exercises and 2023 ESPP instead of Private Placement offering
- Notes:
- The comparison involves different fiscal periods (nine months vs. three months) rather than risk factors disclosure, suggesting these sections may be from MD&A rather than Item 1A Risk Factors
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 4 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 4 sells ($256577) — 4 selling insiders
- Last 180 days0 buys · 6 sells ($280110) — 4 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-01. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about LXEO's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding LXEO as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 12,549,200
- Reported value $72,032,410
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 0 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
LXEO had 17,054,582 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
LXEO had 20.8% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 16.87 days to cover at the same settlement.
- Reported short interest (shares) 17,054,582
- Short interest (% of shares outstanding) 20.8%
- Prior settlement (shares) 16,348,536
- Reported change 4.32%
- Days to cover (reported) 16.87
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Rocket Pharmaceuticals (RCKT)
- Beam Therapeutics (BEAM)
- Editas Medicine (EDIT)
- Intellia Therapeutics (NTLA)
- Sarepta Therapeutics (SRPT)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare LXEO vs…
Frequently asked questions
What does LEXEO THERAPEUTICS INC (LXEO) do?
Lexeo Therapeutics is a clinical-stage genetic medicine company developing therapeutic candidates to treat cardiovascular diseases by targeting underlying genetic causes. The company's lead program, LX2006, is being evaluated in Phase 1/2 trials for Friedreich ataxia cardiomyopathy, with additional programs targeting cardiomyopathy associated with PKP2 mutations and arrhythmogenic cardiomyopathy.
What sector is LEXEO THERAPEUTICS INC (LXEO) in?
LEXEO THERAPEUTICS INC (LXEO) is classified in the Health Care sector. Its industry is Genetic medicine / gene therapy for rare cardiovascular diseases. It trades on NASDAQ.
Who are LEXEO THERAPEUTICS INC's (LXEO) competitors?
Notable peers of LEXEO THERAPEUTICS INC (LXEO) include Rocket Pharmaceuticals, Beam Therapeutics, Editas Medicine, Intellia Therapeutics and Sarepta Therapeutics. This peer set is informational only — not financial advice.
Is LEXEO THERAPEUTICS INC (LXEO) overbought or oversold right now?
LEXEO THERAPEUTICS INC (LXEO) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 52, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on LXEO come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.